Unlike NSCLC, where biomarkers such as tumor mutation burden (TMB) and PD-L1 have shown predictive value for the response to ICIs, SCLC lacks reliable biomarkers for guiding effective therapies [57]. The gene discussed is CD274; the disease is neoplasm.